Treatment  ||| S:0 E:10 ||| NN
goals  ||| S:10 E:16 ||| NNS
in  ||| S:16 E:19 ||| IN
psoriasis  ||| S:19 E:29 ||| JJ
routine  ||| S:29 E:37 ||| JJ
care  ||| S:37 E:42 ||| NN
The  ||| S:42 E:46 ||| DT
treatment  ||| S:46 E:56 ||| NN
goal  ||| S:56 E:61 ||| NN
algorithm  ||| S:61 E:71 ||| NN
for  ||| S:71 E:75 ||| IN
psoriasis ||| S:75 E:84 ||| NN
,  ||| S:84 E:86 ||| ,
first  ||| S:86 E:92 ||| RB
originated  ||| S:92 E:103 ||| VBN
in  ||| S:103 E:106 ||| IN
2007 ||| S:106 E:110 ||| CD
,  ||| S:110 E:112 ||| ,
has  ||| S:112 E:116 ||| VBZ
ever  ||| S:116 E:121 ||| RB
since  ||| S:121 E:127 ||| IN
been  ||| S:127 E:132 ||| VBN
adopted  ||| S:132 E:140 ||| VBN
into  ||| S:140 E:145 ||| IN
treatment  ||| S:145 E:155 ||| NN
guidelines ||| S:155 E:165 ||| NNS
.  ||| S:165 E:167 ||| .
It  ||| S:167 E:170 ||| PRP
remained  ||| S:170 E:179 ||| VBD
unclear  ||| S:179 E:187 ||| JJ
how  ||| S:187 E:191 ||| WRB
many  ||| S:191 E:196 ||| JJ
patients  ||| S:196 E:205 ||| NNS
have  ||| S:205 E:210 ||| VBP
experienced  ||| S:210 E:222 ||| VBN
the  ||| S:222 E:226 ||| DT
use  ||| S:226 E:230 ||| NN
of  ||| S:230 E:233 ||| IN
treatment  ||| S:233 E:243 ||| NN
goals  ||| S:243 E:249 ||| NNS
in  ||| S:249 E:252 ||| IN
routine  ||| S:252 E:260 ||| JJ
care  ||| S:260 E:265 ||| NN
and  ||| S:265 E:269 ||| CC
how  ||| S:269 E:273 ||| WRB
these  ||| S:273 E:279 ||| DT
are  ||| S:279 E:283 ||| VBP
perceived ||| S:283 E:292 ||| VBN
.  ||| S:292 E:294 ||| .
The  ||| S:294 E:298 ||| DT
aim  ||| S:298 E:302 ||| NN
of  ||| S:302 E:305 ||| IN
the  ||| S:305 E:309 ||| DT
pilot  ||| S:309 E:315 ||| NN
study  ||| S:315 E:321 ||| NN
was  ||| S:321 E:325 ||| VBD
to  ||| S:325 E:328 ||| TO
get  ||| S:328 E:332 ||| VB
first  ||| S:332 E:338 ||| JJ
insight  ||| S:338 E:346 ||| NN
in  ||| S:346 E:349 ||| IN
the  ||| S:349 E:353 ||| DT
use  ||| S:353 E:357 ||| NN
and  ||| S:357 E:361 ||| CC
impact  ||| S:361 E:368 ||| NN
of  ||| S:368 E:371 ||| IN
therapeutic  ||| S:371 E:383 ||| JJ
goals  ||| S:383 E:389 ||| NNS
in  ||| S:389 E:392 ||| IN
a  ||| S:392 E:394 ||| DT
large  ||| S:394 E:400 ||| JJ
cohort  ||| S:400 E:407 ||| NN
of  ||| S:407 E:410 ||| IN
patients  ||| S:410 E:419 ||| NNS
with  ||| S:419 E:424 ||| IN
psoriasis  ||| S:424 E:434 ||| NN
in  ||| S:434 E:437 ||| IN
routine  ||| S:437 E:445 ||| JJ
care ||| S:445 E:449 ||| NN
.  ||| S:449 E:451 ||| .
This  ||| S:451 E:456 ||| DT
study  ||| S:456 E:462 ||| NN
is  ||| S:462 E:465 ||| VBZ
a  ||| S:465 E:467 ||| DT
multicenter ||| S:467 E:478 ||| NN
,  ||| S:478 E:480 ||| ,
non-interventional ||| S:480 E:498 ||| NNP
,  ||| S:498 E:500 ||| ,
cross-sectional  ||| S:500 E:516 ||| JJ
health  ||| S:516 E:523 ||| NN
care  ||| S:523 E:528 ||| NN
study  ||| S:528 E:534 ||| NN
in  ||| S:534 E:537 ||| IN
n  ||| S:537 E:539 ||| CD
=  ||| S:539 E:541 ||| SYM
213  ||| S:541 E:545 ||| CD
dermatology  ||| S:545 E:557 ||| CD
centers  ||| S:557 E:565 ||| NNS
across  ||| S:565 E:572 ||| IN
Germany ||| S:572 E:579 ||| NNP
.  ||| S:579 E:581 ||| .
A  ||| S:581 E:583 ||| DT
standardized  ||| S:583 E:596 ||| JJ
physician  ||| S:596 E:606 ||| NN
and  ||| S:606 E:610 ||| CC
patient  ||| S:610 E:618 ||| JJ
questionnaire  ||| S:618 E:632 ||| NN
was  ||| S:632 E:636 ||| VBD
used ||| S:636 E:640 ||| VBN
,  ||| S:640 E:642 ||| ,
including  ||| S:642 E:652 ||| VBG
demographics ||| S:652 E:664 ||| NNS
,  ||| S:664 E:666 ||| ,
disease  ||| S:666 E:674 ||| NN
and  ||| S:674 E:678 ||| CC
treatment  ||| S:678 E:688 ||| NN
characteristics ||| S:688 E:703 ||| NNS
.  ||| S:703 E:705 ||| .
To  ||| S:705 E:708 ||| TO
evaluate  ||| S:708 E:717 ||| VB
patient  ||| S:717 E:725 ||| JJ
treatment  ||| S:725 E:735 ||| NN
perception  ||| S:735 E:746 ||| NN
and  ||| S:746 E:750 ||| CC
satisfaction ||| S:750 E:762 ||| NN
,  ||| S:762 E:764 ||| ,
a  ||| S:764 E:766 ||| DT
questionnaire  ||| S:766 E:780 ||| NN
( ||| S:780 E:781 ||| -LRB-
PsoSat ||| S:781 E:787 ||| NNP
)  ||| S:787 E:789 ||| -RRB-
addressing  ||| S:789 E:800 ||| VBG
8  ||| S:800 E:802 ||| CD
specific  ||| S:802 E:811 ||| JJ
items  ||| S:811 E:817 ||| NNS
was  ||| S:817 E:821 ||| VBD
designed ||| S:821 E:829 ||| VBN
.  ||| S:829 E:831 ||| .
Consistency  ||| S:831 E:843 ||| NNP
and  ||| S:843 E:847 ||| CC
validity  ||| S:847 E:856 ||| NN
of  ||| S:856 E:859 ||| IN
the  ||| S:859 E:863 ||| DT
questionnaire  ||| S:863 E:877 ||| NN
were  ||| S:877 E:882 ||| VBD
controlled  ||| S:882 E:893 ||| VBN
by  ||| S:893 E:896 ||| IN
factor  ||| S:896 E:903 ||| NN
analyses  ||| S:903 E:912 ||| NNS
and  ||| S:912 E:916 ||| CC
reliability  ||| S:916 E:928 ||| JJ
tests ||| S:928 E:933 ||| NNS
.  ||| S:933 E:935 ||| .
In  ||| S:935 E:938 ||| IN
total  ||| S:938 E:944 ||| JJ
n  ||| S:944 E:946 ||| NN
=  ||| S:946 E:948 ||| SYM
1,883  ||| S:948 E:954 ||| CD
patients  ||| S:954 E:963 ||| NNS
were  ||| S:963 E:968 ||| VBD
included  ||| S:968 E:977 ||| VBN
for  ||| S:977 E:981 ||| IN
analysis  ||| S:981 E:990 ||| NN
( ||| S:990 E:991 ||| -LRB-
54.2 ||| S:991 E:995 ||| NNP
%  ||| S:995 E:997 ||| NN
male ||| S:997 E:1001 ||| NN
) ||| S:1001 E:1002 ||| -RRB-
.  ||| S:1002 E:1004 ||| .
Mean  ||| S:1004 E:1009 ||| JJ
age  ||| S:1009 E:1013 ||| NN
was  ||| S:1013 E:1017 ||| VBD
52  ||| S:1017 E:1020 ||| CD
years ||| S:1020 E:1025 ||| NNS
,  ||| S:1025 E:1027 ||| ,
mean  ||| S:1027 E:1032 ||| JJ
disease  ||| S:1032 E:1040 ||| NN
duration  ||| S:1040 E:1049 ||| NN
19  ||| S:1049 E:1052 ||| CD
years ||| S:1052 E:1057 ||| NNS
.  ||| S:1057 E:1059 ||| .
In  ||| S:1059 E:1062 ||| IN
total  ||| S:1062 E:1068 ||| JJ
45.5 ||| S:1068 E:1072 ||| CD
%  ||| S:1072 E:1074 ||| NN
( ||| S:1074 E:1075 ||| -LRB-
n  ||| S:1075 E:1077 ||| CD
=  ||| S:1077 E:1079 ||| SYM
856 ||| S:1079 E:1082 ||| CD
)  ||| S:1082 E:1084 ||| -RRB-
stated  ||| S:1084 E:1091 ||| VBD
an  ||| S:1091 E:1094 ||| DT
improvement  ||| S:1094 E:1106 ||| NN
of  ||| S:1106 E:1109 ||| IN
psoriatic  ||| S:1109 E:1119 ||| JJ
symptoms  ||| S:1119 E:1128 ||| NNS
in  ||| S:1128 E:1131 ||| IN
the  ||| S:1131 E:1135 ||| DT
last  ||| S:1135 E:1140 ||| JJ
4  ||| S:1140 E:1142 ||| CD
weeks ||| S:1142 E:1147 ||| NNS
.  ||| S:1147 E:1149 ||| .
In  ||| S:1149 E:1152 ||| IN
patients  ||| S:1152 E:1161 ||| NNS
including  ||| S:1161 E:1171 ||| VBG
treatment  ||| S:1171 E:1181 ||| NN
goals ||| S:1181 E:1186 ||| NNS
,  ||| S:1186 E:1188 ||| ,
the  ||| S:1188 E:1192 ||| DT
course  ||| S:1192 E:1199 ||| NN
of  ||| S:1199 E:1202 ||| IN
psoriasis  ||| S:1202 E:1212 ||| NN
in  ||| S:1212 E:1215 ||| IN
the  ||| S:1215 E:1219 ||| DT
last  ||| S:1219 E:1224 ||| JJ
4  ||| S:1224 E:1226 ||| CD
weeks  ||| S:1226 E:1232 ||| NNS
was  ||| S:1232 E:1236 ||| VBD
rated  ||| S:1236 E:1242 ||| VBN
significantly  ||| S:1242 E:1256 ||| RB
better  ||| S:1256 E:1263 ||| JJR
and  ||| S:1263 E:1267 ||| CC
predicted  ||| S:1267 E:1277 ||| VBD
significantly  ||| S:1277 E:1291 ||| RB
higher  ||| S:1291 E:1298 ||| JJR
patient  ||| S:1298 E:1306 ||| NN
satisfaction ||| S:1306 E:1318 ||| NN
.  ||| S:1318 E:1320 ||| .
Patients  ||| S:1320 E:1329 ||| NNS
reporting  ||| S:1329 E:1339 ||| VBG
periodic  ||| S:1339 E:1348 ||| JJ
outcomes  ||| S:1348 E:1357 ||| JJ
measurement  ||| S:1357 E:1369 ||| NN
of  ||| S:1369 E:1372 ||| IN
psoriasis  ||| S:1372 E:1382 ||| JJ
treatment ||| S:1382 E:1391 ||| NN
,  ||| S:1391 E:1393 ||| ,
also  ||| S:1393 E:1398 ||| RB
had  ||| S:1398 E:1402 ||| VBD
significantly  ||| S:1402 E:1416 ||| RB
better  ||| S:1416 E:1423 ||| JJR
course  ||| S:1423 E:1430 ||| NN
of  ||| S:1430 E:1433 ||| IN
disease ||| S:1433 E:1440 ||| NN
,  ||| S:1440 E:1442 ||| ,
higher  ||| S:1442 E:1449 ||| JJR
satisfaction  ||| S:1449 E:1462 ||| NN
and  ||| S:1462 E:1466 ||| CC
a  ||| S:1466 E:1468 ||| DT
lower  ||| S:1468 E:1474 ||| JJR
psoriasis  ||| S:1474 E:1484 ||| JJ
severity ||| S:1484 E:1492 ||| NN
.  ||| S:1492 E:1494 ||| .
A  ||| S:1494 E:1496 ||| DT
majority  ||| S:1496 E:1505 ||| NN
of  ||| S:1505 E:1508 ||| IN
patients  ||| S:1508 E:1517 ||| NNS
experienced  ||| S:1517 E:1529 ||| VBD
the  ||| S:1529 E:1533 ||| DT
use  ||| S:1533 E:1537 ||| NN
of  ||| S:1537 E:1540 ||| IN
treatment  ||| S:1540 E:1550 ||| NN
goals  ||| S:1550 E:1556 ||| NNS
in  ||| S:1556 E:1559 ||| IN
practice ||| S:1559 E:1567 ||| NN
.  ||| S:1567 E:1569 ||| .
The  ||| S:1569 E:1573 ||| DT
association  ||| S:1573 E:1585 ||| NN
of  ||| S:1585 E:1588 ||| IN
using  ||| S:1588 E:1594 ||| VBG
treatment  ||| S:1594 E:1604 ||| NN
goals  ||| S:1604 E:1610 ||| NNS
with  ||| S:1610 E:1615 ||| IN
clinical  ||| S:1615 E:1624 ||| JJ
outcomes  ||| S:1624 E:1633 ||| NNS
and  ||| S:1633 E:1637 ||| CC
treatment  ||| S:1637 E:1647 ||| NN
satisfaction  ||| S:1647 E:1660 ||| NN
was  ||| S:1660 E:1664 ||| VBD
markedly  ||| S:1664 E:1673 ||| RB
positive ||| S:1673 E:1681 ||| JJ
.  ||| S:1681 E:1683 ||| .
These  ||| S:1683 E:1689 ||| DT
findings  ||| S:1689 E:1698 ||| NNS
indicate  ||| S:1698 E:1707 ||| VBP
that  ||| S:1707 E:1712 ||| IN
the  ||| S:1712 E:1716 ||| DT
use  ||| S:1716 E:1720 ||| NN
of  ||| S:1720 E:1723 ||| IN
treatment  ||| S:1723 E:1733 ||| NN
goals  ||| S:1733 E:1739 ||| NNS
and  ||| S:1739 E:1743 ||| CC
outcome  ||| S:1743 E:1751 ||| NN
measurements  ||| S:1751 E:1764 ||| NNS
in  ||| S:1764 E:1767 ||| IN
fact  ||| S:1767 E:1772 ||| NN
improve  ||| S:1772 E:1780 ||| VB
psoriasis  ||| S:1780 E:1790 ||| JJ
management ||| S:1790 E:1800 ||| NN
.  ||| S:1800 E:1802 ||| .
